Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Upcoming Events

Refining Strategies for Enhancing Cardiorenal Outcomes with SGLT2 Inhibitors: Optimizing the Cardiometabolic Care Model 

Review multidisciplinary care team approaches to managing cardio-renal-metabolic disease using emerging evidence and evolving treatment guidelines.

Live Broadcast
1.00 available credits
Information
December 3, 2024
01:30 PM - 02:30 PM EST
ReachMD Healthcare Image

This live broadcast will start in exactly:

  • 0

    Day(s)

  • 0

    Hour(s)

  • 0

    Minute(s)

  • 0

    Second(s)

Details
Presenters
Related
Comments
  • Overview

    In this live webinar, a multidisciplinary faculty panel will review emerging evidence and evolving treatment guidelines related to cardio-renal-metabolic comorbidities (ie, type 2 diabetes, heart failure, chronic kidney disease, and management of post-MI) using clinical patience case vignettes. 

  • Agenda

    1:30 – 1:35 PM

     

    Welcome and Introduction

    Melissa Magwire, RN

    1:35 – 1:45 PM

     

     

    Cardiologist Best Practices in the Management of Cardiometabolic Renal Outcomes

    Keith Miller, MD 

    1:45 – 1:55 PM

     

     

    Nursing Best Practices in the Management of Cardiometabolic Renal Outcomes

    Melissa Magwire, RN

    1:55 – 2:05 PM

    Pharmacy Best Practices in the Management of Cardiometabolic Renal Outcomes 

    Matthew Bullington, PharmD

     

    2:05 – 2:15 PM

     

    APP Best Practices in the Management of Cardiometabolic Renal Outcomes 

    Dawn M. Denicola, NP

     

    2:15 – 2:25 PM

    Expert Panel Discussion – Pulling It All Together

    All Faculty

     

    2:25 – 2:30 PM

    Live Q&A

    All Faculty

     

     

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Melissa Magwire, RN, MSN, CDE
    Program Director, Cardiometabolic Center Alliance
    St. Luke’s Health System
    Kansas City, MO

    Melissa Magwire has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Amgen, Boehringer Ingelheim, Novo Nordisk  

    Faculty:
    Matthew Bullington, PharmD
    MHP Primary and Specialty Care
    Shelbyville, IN

    Matthew Bullington has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Has reported no relevant relationships at this time

    Dawn M. Denicola, FNP-C
    Family Nurse Practitioner
    Baton Rouge, LA

    Dawn Denicola has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Has reported no relevant relationships at this time

    Keith Miller, MD
    Cardiologist
    Bryan Heart
    Lincoln, NE

    Dr. Miller has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Has reported no relevant relationships at this time

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Examine the clinical traits of chronic kidney disease (CKD) for prompt diagnosis and treatment initiation 
    • Assess the real-world implications of recent clinical trial findings on SGLT2 inhibitors for disease progression in a diverse patient population with CKD and/or heart failure (HF) 
    • Incorporate the ADA-KDIGO consensus recommendations along with other guidelines such as ESC-HF, ADA, and AHA in designing treatment protocols for patients suffering from CKD and/or HF, irrespective of their diabetes status
    • Develop strategies for using SGLT2 inhibitors in patients with and without diabetes to improve cardiorenal outcomes 
    • Apply approaches to coordinated interdisciplinary care for patients with cardiorenal metabolic disease   
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, and primary care physicians, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other members of the interprofessional team who are involved in the management of patients with CVRM. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is UAN JA0006235-0000-24-145-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit(s). Approval is valid until December 6, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Details
Presenters
Related
Comments
Recommended
  • Overview

    In this live webinar, a multidisciplinary faculty panel will review emerging evidence and evolving treatment guidelines related to cardio-renal-metabolic comorbidities (ie, type 2 diabetes, heart failure, chronic kidney disease, and management of post-MI) using clinical patience case vignettes. 

  • Agenda

    1:30 – 1:35 PM

     

    Welcome and Introduction

    Melissa Magwire, RN

    1:35 – 1:45 PM

     

     

    Cardiologist Best Practices in the Management of Cardiometabolic Renal Outcomes

    Keith Miller, MD 

    1:45 – 1:55 PM

     

     

    Nursing Best Practices in the Management of Cardiometabolic Renal Outcomes

    Melissa Magwire, RN

    1:55 – 2:05 PM

    Pharmacy Best Practices in the Management of Cardiometabolic Renal Outcomes 

    Matthew Bullington, PharmD

     

    2:05 – 2:15 PM

     

    APP Best Practices in the Management of Cardiometabolic Renal Outcomes 

    Dawn M. Denicola, NP

     

    2:15 – 2:25 PM

    Expert Panel Discussion – Pulling It All Together

    All Faculty

     

    2:25 – 2:30 PM

    Live Q&A

    All Faculty

     

     

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Melissa Magwire, RN, MSN, CDE
    Program Director, Cardiometabolic Center Alliance
    St. Luke’s Health System
    Kansas City, MO

    Melissa Magwire has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Amgen, Boehringer Ingelheim, Novo Nordisk  

    Faculty:
    Matthew Bullington, PharmD
    MHP Primary and Specialty Care
    Shelbyville, IN

    Matthew Bullington has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Has reported no relevant relationships at this time

    Dawn M. Denicola, FNP-C
    Family Nurse Practitioner
    Baton Rouge, LA

    Dawn Denicola has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Has reported no relevant relationships at this time

    Keith Miller, MD
    Cardiologist
    Bryan Heart
    Lincoln, NE

    Dr. Miller has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Has reported no relevant relationships at this time

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Examine the clinical traits of chronic kidney disease (CKD) for prompt diagnosis and treatment initiation 
    • Assess the real-world implications of recent clinical trial findings on SGLT2 inhibitors for disease progression in a diverse patient population with CKD and/or heart failure (HF) 
    • Incorporate the ADA-KDIGO consensus recommendations along with other guidelines such as ESC-HF, ADA, and AHA in designing treatment protocols for patients suffering from CKD and/or HF, irrespective of their diabetes status
    • Develop strategies for using SGLT2 inhibitors in patients with and without diabetes to improve cardiorenal outcomes 
    • Apply approaches to coordinated interdisciplinary care for patients with cardiorenal metabolic disease   
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, and primary care physicians, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other members of the interprofessional team who are involved in the management of patients with CVRM. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is UAN JA0006235-0000-24-145-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit(s). Approval is valid until December 6, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Schedule21 Nov 2024